Long-Term PPI Risks: Is Daily Omeprazole Safe?

What are PPIs and why are they prescribed long-term?

Proton pump inhibitors (PPIs) — omeprazole, pantoprazole, lansoprazole, esomeprazole, and others — work by blocking the enzyme that produces stomach acid, reducing acid output by 90% or more at standard doses. They are effective for:

• Gastroesophageal reflux disease (GERD): Long-term use is appropriate for patients with confirmed erosive esophagitis, Barrett's esophagus, or who have tried step-down and experienced relapse 1Ref 1Yadlapati R, Gyawali CP, Pandolfino JE; CGIT GERD Consensus Conference Participants (2022).AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review.Appropriate PPI use, step-down strategies, and long-term safety considerations in GERD; when ongoing PPI therapy is warranted versus when to attempt deprescribing2Ref 2Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ (2022).ACG Clinical Guideline: Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease.ACG position on long-term PPI therapy for Barrett's esophagus and erosive esophagitis; periodic reassessment of PPI need; risk-benefit framework for ongoing use
• Barrett's esophagus: PPIs reduce esophageal inflammation and may lower dysplasia risk; ongoing therapy is typically recommended 2Ref 2Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ (2022).ACG Clinical Guideline: Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease.ACG position on long-term PPI therapy for Barrett's esophagus and erosive esophagitis; periodic reassessment of PPI need; risk-benefit framework for ongoing use
• H. pylori eradication: Short-course (1–2 week) use as part of combination therapy
• NSAID prophylaxis: For patients at high GI bleeding risk who need chronic NSAID use
• Zollinger-Ellison syndrome and other hypersecretory conditions

When used for a clear indication at the right dose, PPIs are among the safest medications available. The concern arises when they are used without a verified indication, at higher doses than needed, or indefinitely without reassessment 3Ref 3Targownik LE, Fisher DA, Saini SD (2022).AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.AGA recommendation that all patients on long-term PPIs should have documented ongoing indications; step-down from twice-daily to once-daily; deprescribing reduces costs and theoretical risks; only 27% of long-term users had verified clinical indications4Ref 4Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.Quality of evidence for PPI long-term risks (kidney disease, dementia, fractures, hypomagnesemia, C. difficile) is consistently low to very low; when benefits outweigh risks for appropriate indications; framework for reassessing need.

What are the known risks of long-term PPI use?

Observational studies have identified associations between long-term PPI use and several adverse outcomes. Importantly, most of this evidence is low to very low quality — largely because people who take PPIs for years often have other health conditions that independently raise their risk 4Ref 4Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.Quality of evidence for PPI long-term risks (kidney disease, dementia, fractures, hypomagnesemia, C. difficile) is consistently low to very low; when benefits outweigh risks for appropriate indications; framework for reassessing need.

Hypomagnesemia (low magnesium): The most established risk. PPIs reduce intestinal magnesium absorption; severe cases can cause muscle cramps, irregular heartbeat, and seizures. The FDA issued a safety communication about this risk 4Ref 4Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.Quality of evidence for PPI long-term risks (kidney disease, dementia, fractures, hypomagnesemia, C. difficile) is consistently low to very low; when benefits outweigh risks for appropriate indications; framework for reassessing need.

Vitamin B12 deficiency: Long-term acid suppression reduces B12 absorption from food (though not from supplements). Risk is higher with longer duration and higher doses 4Ref 4Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.Quality of evidence for PPI long-term risks (kidney disease, dementia, fractures, hypomagnesemia, C. difficile) is consistently low to very low; when benefits outweigh risks for appropriate indications; framework for reassessing need.

Bone fractures: Observational studies show a modest increased risk of hip, wrist, and spine fractures (relative risk approximately 1.2 for hip fractures), likely through impaired calcium absorption and possibly reduced bone mineral density 4Ref 4Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.Quality of evidence for PPI long-term risks (kidney disease, dementia, fractures, hypomagnesemia, C. difficile) is consistently low to very low; when benefits outweigh risks for appropriate indications; framework for reassessing need.

Chronic kidney disease: Some large cohort studies show an association, though confounding by indication makes causality uncertain 4Ref 4Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.Quality of evidence for PPI long-term risks (kidney disease, dementia, fractures, hypomagnesemia, C. difficile) is consistently low to very low; when benefits outweigh risks for appropriate indications; framework for reassessing need.

Clostridium difficile infection: Acid suppression may reduce the stomach's bactericidal function, raising infection risk — particularly in hospitalized patients 4Ref 4Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.Quality of evidence for PPI long-term risks (kidney disease, dementia, fractures, hypomagnesemia, C. difficile) is consistently low to very low; when benefits outweigh risks for appropriate indications; framework for reassessing need.

Dementia: Some population studies suggest a signal, but quality of evidence is low and confounding is substantial 4Ref 4Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.Quality of evidence for PPI long-term risks (kidney disease, dementia, fractures, hypomagnesemia, C. difficile) is consistently low to very low; when benefits outweigh risks for appropriate indications; framework for reassessing need.

Do the benefits of PPIs outweigh the risks?

For patients with an appropriate indication, yes — when PPIs are correctly prescribed, their benefits are likely to outweigh their risks 4Ref 4Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.Quality of evidence for PPI long-term risks (kidney disease, dementia, fractures, hypomagnesemia, C. difficile) is consistently low to very low; when benefits outweigh risks for appropriate indications; framework for reassessing need. The AGA expert review found that despite a long list of potential adverse effects, the quality of evidence underlying these associations is consistently low to very low 4Ref 4Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.Quality of evidence for PPI long-term risks (kidney disease, dementia, fractures, hypomagnesemia, C. difficile) is consistently low to very low; when benefits outweigh risks for appropriate indications; framework for reassessing need.

The concern is that many people take PPIs long-term without a clearly verified indication. In one estimate, only about 27% of long-term PPI users had a documented clinical reason for their use 3Ref 3Targownik LE, Fisher DA, Saini SD (2022).AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.AGA recommendation that all patients on long-term PPIs should have documented ongoing indications; step-down from twice-daily to once-daily; deprescribing reduces costs and theoretical risks; only 27% of long-term users had verified clinical indications. For those without a robust indication, the risk-benefit balance may favor deprescribing or step-down.

What monitoring makes sense on long-term PPIs?

If you are on long-term PPI therapy, reasonable monitoring may include 1Ref 1Yadlapati R, Gyawali CP, Pandolfino JE; CGIT GERD Consensus Conference Participants (2022).AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review.Appropriate PPI use, step-down strategies, and long-term safety considerations in GERD; when ongoing PPI therapy is warranted versus when to attempt deprescribing3Ref 3Targownik LE, Fisher DA, Saini SD (2022).AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.AGA recommendation that all patients on long-term PPIs should have documented ongoing indications; step-down from twice-daily to once-daily; deprescribing reduces costs and theoretical risks; only 27% of long-term users had verified clinical indications:

• Reassessment of the indication at least annually — does the original indication still apply? Has a step-down been attempted?
• Serum magnesium if you develop unexplained muscle cramps, weakness, or arrhythmia
• Vitamin B12 after several years of use, especially in older adults or those with dietary restrictions
• Bone density (DEXA scan) per standard screening guidelines — not triggered specifically by PPI use in most cases, but relevant if you have other osteoporosis risk factors

Your prescriber can individualize monitoring based on your dose, duration, and other health conditions.

Can I stop my PPI if I've been on it for years?

Deprescribing PPIs is often possible but requires a plan 3Ref 3Targownik LE, Fisher DA, Saini SD (2022).AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.AGA recommendation that all patients on long-term PPIs should have documented ongoing indications; step-down from twice-daily to once-daily; deprescribing reduces costs and theoretical risks; only 27% of long-term users had verified clinical indications. Key points:

• Never stop abruptly after long-term use without guidance. Acid rebound hypersecretion can cause a temporary worsening of reflux symptoms, which patients may misinterpret as their original condition returning.
• Step-down first: Patients taking twice-daily PPIs should generally step down to once daily before attempting to stop. Once-daily users can try every-other-day dosing or switching to an H2 blocker before stopping entirely 3Ref 3Targownik LE, Fisher DA, Saini SD (2022).AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.AGA recommendation that all patients on long-term PPIs should have documented ongoing indications; step-down from twice-daily to once-daily; deprescribing reduces costs and theoretical risks; only 27% of long-term users had verified clinical indications.
• Conditions that warrant ongoing therapy: Barrett's esophagus, erosive esophagitis (LA grade C or D), and high-risk NSAID use are situations where continued PPI therapy is usually appropriate rather than deprescribing 1Ref 1Yadlapati R, Gyawali CP, Pandolfino JE; CGIT GERD Consensus Conference Participants (2022).AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review.Appropriate PPI use, step-down strategies, and long-term safety considerations in GERD; when ongoing PPI therapy is warranted versus when to attempt deprescribing2Ref 2Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ (2022).ACG Clinical Guideline: Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease.ACG position on long-term PPI therapy for Barrett's esophagus and erosive esophagitis; periodic reassessment of PPI need; risk-benefit framework for ongoing use.

The AGA recommends that all patients on long-term PPIs have the ongoing indication documented and reviewed regularly — ideally by the prescribing primary care clinician 3Ref 3Targownik LE, Fisher DA, Saini SD (2022).AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.AGA recommendation that all patients on long-term PPIs should have documented ongoing indications; step-down from twice-daily to once-daily; deprescribing reduces costs and theoretical risks; only 27% of long-term users had verified clinical indications.